Table 1

Baseline characteristics by prior oral anticoagulation status at randomisation

CharacteristicPrior OACNo prior OACP value†
NOAC
(N=1227)
VKA
(N=1033)
Any OAC*
(N=2262)
(N=2352)
Age, median (25th, 75th), years71, 64–7771, 65–7771, 65–7770, 64–770.040
Female sex, no (%)336 (27.4)276 (26.7)613 (27.1)724 (30.8)0.006
Race, no/No (%)0.018
White1120/1208 (92.7)960/1031 (93.1)2082/2241 (92.9)2102/2316 (90.8)
Black14/1208 (1.2)12/1031 (1.2)26/2241 (1.2)33/2316 (1.4)
Asian35/1208 (2.9)32/1031 (3.1)67/2241 (3.0)73/2316 (3.2)
Other39/1208 (3.2)27/1031 (2.6)66/2241 (2.9)108/2316 (4.7)
Serum creatinine, median (25th, 75th), mg/dL1.0, 0.9–1.21.0, 0.9–1.21.0, 0.9–1.21.0, 0.9–1.20.020
Serum creatinine, no/No (%)0.56
<1.5 mg/dL1114/1210 (92.1%)938/1024 (91.6%)2054/2236 (91.9%)2098/2296 (91.4%)
≥1.5 mg/dL96/1210 (7.9%)86/1024 (8.4%)182/2236 (8.1%)198/2296 (8.6%)
CHA2DS2-VASc score, mean (SD)4.0 (1.5)4.1 (1.6)4.0 (1.5)3.8 (1.6)<0.001
HAS-BLED score, mean (SD)2.9 (0.9)2.9 (1.0)2.9 (1.0)2.8 (0.9)<0.001
Hypertension leading to medication use, no (%)1104 (90.0%)923 (89.4%)2029 (89.7%)2044 (86.9%)0.003
Heart failure, no (%)546 (44.5%)510 (49.4%)1056 (46.7%)917 (39.0%)<0.001
Diabetes mellitus, no (%)472 (38.5%)399 (38.6%)872 (38.5%)806 (34.3%)0.003
Stroke, TIA, or thromboembolism, no/No (%)171/1218 (14.0%)173/1027 (16.8%)344/2247 (15.3%)289/2334 (12.4%)0.004
Concomitant P2Y12 inhibitor, no (%)<0.001
Clopidogrel1123 (91.5%)985 (95.4%)2110 (93.3%)2055 (87.4%)
Ticagrelor66 (5.4%)25 (2.4%)91 (4.0%)189 (8.0%)
Prasugrel15 (1.2%)6 (0.6%)21 (0.9%)30 (1.3%)
None23 (1.9%)17 (1.6%)40 (1.8%)78 (3.3%)
Qualifying index event, no/No (%)<0.001
ACS and PCI418/1223 (34.2%)294/1031 (28.5%)712/2256 (31.6%)1002/2339 (42.8%)
Medically managed ACS216/1223 (17.7%)305/1031 (29.6%)521/2256 (23.1%)576/2339 (24.6%)
Elective PCI589/1223 (48.2%)432/1031 (41.9%)1023/2256 (45.3%)761/2339 (32.5%)
Days from ACS or PCI to randomisation, mean (SD)6.7 (4.3)7.0 (4.2)6.8 (4.3)6.4 (4.1)0.001
On OAC prior to index event, no/No (%)827/1227 (67.4%)677/1033 (65.5%)1505/2262 (66.5%)
  • For patients reporting more than one type of anticoagulant, the most recent type is used.

  • *Two patients reported prior oral anticoagulant use but information about the type of anticoagulant was not reported; they were included in the ‘any OAC’ group.

  • †P value compares ‘any OAC’ versus ‘no prior OAC’ columns.

  • ACS, acute coronary syndrome; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; VKA, vitamin K antagonist.